Literature DB >> 25477594

Drug monographs: ibrutinib and ramucirumab.

Dominic A Solimando, J Aubrey Waddell.   

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

Entities:  

Year:  2014        PMID： 25477594      PMCID： PMC4252197          DOI： 10.1310/hpj4908-702

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  19 in total

1.  Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.

Authors:  Susan O'Brien; Richard R Furman; Steven E Coutre; Jeff P Sharman; Jan A Burger; Kristie A Blum; Barbara Grant; Donald A Richards; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Raquel Izumi; Ahmed Hamdy; Betty Y Chang; Thorsten Graef; Fong Clow; Joseph J Buggy; Danelle F James; John C Byrd
Journal:  Lancet Oncol       Date:  2013-12-10       Impact factor: 41.316

2.  Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.

Authors:  M Prewett; J Huber; Y Li; A Santiago; W O'Connor; K King; J Overholser; A Hooper; B Pytowski; L Witte; P Bohlen; D J Hicklin
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

3.  The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.

Authors:  Sabine Ponader; Shih-Shih Chen; Joseph J Buggy; Kumudha Balakrishnan; Varsha Gandhi; William G Wierda; Michael J Keating; Susan O'Brien; Nicholas Chiorazzi; Jan A Burger
Journal:  Blood       Date:  2011-12-16       Impact factor: 22.113

4.  The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.

Authors:  Lee A Honigberg; Ashley M Smith; Mint Sirisawad; Erik Verner; David Loury; Betty Chang; Shyr Li; Zhengying Pan; Douglas H Thamm; Richard A Miller; Joseph J Buggy
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-06       Impact factor: 11.205

5.  TRIO-012: a multicenter, multinational, randomized, double-blind phase III study of IMC-1121B plus docetaxel versus placebo plus docetaxel in previously untreated patients with HER2-negative, unresectable, locally recurrent or metastatic breast cancer.

Authors:  John Mackey; Karen Gelmon; Miguel Martin; Nicole McCarthy; Tamas Pinter; Mathieu Rupin; Hagop Youssoufian
Journal:  Clin Breast Cancer       Date:  2009-11       Impact factor: 3.225

6.  Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

Authors:  Ranjana H Advani; Joseph J Buggy; Jeff P Sharman; Sonali M Smith; Thomas E Boyd; Barbara Grant; Kathryn S Kolibaba; Richard R Furman; Sara Rodriguez; Betty Y Chang; Juthamas Sukbuntherng; Raquel Izumi; Ahmed Hamdy; Eric Hedrick; Nathan H Fowler
Journal:  J Clin Oncol       Date:  2012-10-08       Impact factor: 44.544

7.  Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.

Authors:  Jennifer L Spratlin; Roger B Cohen; Matthew Eadens; Lia Gore; D Ross Camidge; Sami Diab; Stephen Leong; Cindy O'Bryant; Laura Q M Chow; Natalie J Serkova; Neal J Meropol; Nancy L Lewis; E Gabriela Chiorean; Floyd Fox; Hagop Youssoufian; Eric K Rowinsky; S Gail Eckhardt
Journal:  J Clin Oncol       Date:  2010-01-04       Impact factor: 44.544

8.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Authors:  Michael L Wang; Simon Rule; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Lei Li; Liang Zhang; Kate Newberry; Zhishuo Ou; Nancy Cheng; Bingliang Fang; Jesse McGreivy; Fong Clow; Joseph J Buggy; Betty Y Chang; Darrin M Beaupre; Lori A Kunkel; Kristie A Blum
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

9.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

10.  The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells.

Authors:  Betty Y Chang; Min Mei Huang; Michelle Francesco; Jun Chen; Jeremy Sokolove; Padmaja Magadala; William H Robinson; Joseph J Buggy
Journal:  Arthritis Res Ther       Date:  2011-07-13       Impact factor: 5.156
View more
  1 in total

Review 1.  Bruton's tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation.

Authors:  Maude Sestier; Christopher Hillis; Graeme Fraser; Darryl Leong
Journal:  Curr Oncol Rep       Date:  2021-08-03       Impact factor: 5.075
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.